Hb Wealth Management 13F: Adds $1.3M to BMY Stake

Hb Wealth Management Raises Stake in Bristol-Myers Squibb

Hb Wealth Management expanded its investment in Bristol-Myers Squibb Company BMY by purchasing an additional 22,867 shares during the period. The transaction, detailed in a Form 13F filing with the Securities and Exchange Commission, lifted the firm's total ownership to 109,993 shares. Based on market prices around the filing date, the stake carried a reported value of about $6.33 million.

Details of the Portfolio Change

Before this adjustment, Hb Wealth Management held 87,126 shares of the pharmaceutical company. The addition of 22,867 shares represents a 26.2% increase in the fund's position. Because 13F filings look backward at holdings from the close of the reporting quarter, the figures reflect past positioning and may not capture current trading activity by the firm.

Bristol-Myers Squibb Stock Performance

Bristol-Myers Squibb shares recently changed hands at $57.62. The equity has moved between a 52-week low of $42.52 and a high of $68.64. The company currently carries a market capitalization of $123.73 billion. Its valuation metrics include a trailing price-to-earnings ratio of 13.3 and a forward price-to-earnings ratio of 9.1.

Dividend and Yield Metrics

Income-focused investors tracking the healthcare giant will note its annualized dividend payout. The stock yields 4.16%, supported by a dividend payout ratio of 55.29%. Management distributes these payouts to shareholders on a regular schedule while funding ongoing drug discovery efforts.

Analysts Set New Price Targets

Market research firms have updated their outlooks on Bristol-Myers Squibb through the autumn months. On October 13, 2026, Wells Fargo maintained an equal-weight rating while adjusting its price target to $60.00 from $65.00. Cantor Fitzgerald kept a neutral rating on October 8, 2026, lowering its target to $53.00. Morgan Stanley maintained an underweight rating on October 7, 2026, moving its target to $41.00. Leerink Partners downgraded the stock to market perform on October 5, 2026, setting a $59.00 target. Piper Sandler reiterated an overweight rating on September 16, 2026, with an $82.00 target. HSBC maintained a hold rating on September 10, 2026, with a $65.00 target. Argus Research upgraded the stock to a buy on August 5, 2026, at a $75.00 target, and Citigroup maintained a neutral rating on August 3, 2026, at $70.00. Overall, the stock holds a consensus buy recommendation from 24 analysts, with a mean target price of $65.63.

About Bristol-Myers Squibb

Headquartered in Princeton, New Jersey, Bristol-Myers Squibb discovers and distributes biopharmaceutical treatments worldwide. The enterprise focuses on therapeutic areas such as oncology, hematology, immunology, cardiovascular disease, and neuroscience. Its product catalog features widely prescribed therapies like Eliquis, Opdivo, and Pomalyst, serving hospitals, clinics, and pharmacies globally.

What to Watch at Bristol-Myers Squibb Company

The company is scheduled to release its next financial results on October 29, 2026. Market observers will review subsequent institutional filings to see if Hb Wealth Management and other major asset managers continue altering their exposure to the healthcare sector.